A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. or A drug used before autologous stem cell transplantation in patients with non-Hodgkin lymphoma or multiple myeloma. Plerixafor is given together with granulocyte-colony stimulating factor (G-CSF) to help move stem cells from the bone marrow to the blood. The stem cells can then be collected, stored, and given back to the patient. Plerixafor is a type of chemokine receptor antagonist. Also called AMD 3100 and Mozobil.